Literature DB >> 18650353

Metronidazole resistance in Clostridium difficile is heterogeneous.

T Peláez1, E Cercenado, L Alcalá, M Marín, A Martín-López, J Martínez-Alarcón, P Catalán, M Sánchez-Somolinos, E Bouza.   

Abstract

At our institution, the prevalence of clinical isolates of Clostridium difficile with resistance to metronidazole is 6.3%. We observed that initial metronidazole MICs of 16 to 64 mg/liter against toxigenic, primary fresh C. difficile isolates, as determined by agar dilution, decreased to 0.125 mg/liter after the isolates were thawed. In this study, we examined the possibility of heterogeneous or inducible resistance. Totals of 14 metronidazole-resistant and 10 metronidazole-susceptible clinical isolates of toxigenic C. difficile were studied. The isolates were investigated for the presence of nim genes by PCR. After the isolates were thawed, susceptibility testing was done by agar dilution, by disc diffusion using a 5-mug metronidazole disc, and by the Etest method. An experiment for determining the effect of prolonged exposure to metronidazole was applied to all resistant isolates and to susceptible control strains. None of the isolates presented the nim genes. All initially metronidazole-resistant C. difficile isolates became susceptible after thawing; however, they presented slow-growing subpopulations within the inhibition zones of both the disk and the Etest strip. All metronidazole-susceptible isolates remained homogeneously susceptible by both methods. After prolonged exposure in vitro to metronidazole, no zone of inhibition was found around the 5-microg disk in any of the metronidazole-resistant isolates, and the MICs as determined by the Etest method ranged from 0.125 to >256 mg/liter, with colonies growing inside the inhibition zone. Our results indicate that (i) resistance to metronidazole was not due to the presence of nim genes, (ii) resistance to metronidazole in toxigenic C. difficile isolates is heterogeneous, and (iii) prolonged exposure to metronidazole can select for in vitro resistance. We recommend routine performance of the disk diffusion method (5-microg metronidazole disk) with primary fresh C. difficile isolates in order to ensure that metronidazole-heteroresistant populations do not go undetected.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650353      PMCID: PMC2546748          DOI: 10.1128/JCM.00524-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Reduced susceptibility of Clostridium difficile to metronidazole.

Authors:  J S Brazier; W Fawley; J Freeman; M H Wilcox
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

Review 2.  Recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; C P Kelly
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile.

Authors:  I Poilane; P Cruaud; J C Torlotin; A Collignon
Journal:  Clin Microbiol Infect       Date:  2000-03       Impact factor: 8.067

4.  Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Authors:  F Barbut; D Decré; B Burghoffer; D Lesage; F Delisle; V Lalande; M Delmée; V Avesani; N Sano; C Coudert; J C Petit
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Assessment of optimal atmospheric conditions for growth of Helicobacter pylori.

Authors:  T H Henriksen; A Lia; R Schøyen; T Thoresen; A Berstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-09       Impact factor: 3.267

6.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants.

Authors:  Micaela Gal; J S Brazier
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

8.  Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination.

Authors:  T H Henriksen; F Lerang; A Lia; R Schøyen; T Thoresen; T Berge; E Ragnhildstveit; Y Tveten; A Berstad
Journal:  Clin Microbiol Infect       Date:  2004-04       Impact factor: 8.067

9.  Heteroresistance: a concern of increasing clinical significance?

Authors:  M E Falagas; G C Makris; G Dimopoulos; D K Matthaiou
Journal:  Clin Microbiol Infect       Date:  2007-12-18       Impact factor: 8.067

10.  Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin.

Authors:  G D Rifkin; F R Fekety; J Silva
Journal:  Lancet       Date:  1977-11-26       Impact factor: 79.321

View more
  56 in total

Review 1.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

3.  Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.

Authors:  L Alcalá; E Reigadas; M Marín; A Martín; P Catalán; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-24       Impact factor: 3.267

Review 4.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 5.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

6.  Action of nitroheterocyclic drugs against Clostridium difficile.

Authors:  Manish Kumar; Sudip Adhikari; Julian G Hurdle
Journal:  Int J Antimicrob Agents       Date:  2014-07-25       Impact factor: 5.283

7.  Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.

Authors:  Vladimir Beran; Dittmar Chmelar; Jana Vobejdova; Adela Konigova; Jakub Nemec; Josef Tvrdik
Journal:  Folia Microbiol (Praha)       Date:  2013-10-11       Impact factor: 2.099

8.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

9.  Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole.

Authors:  Ines Moura; Marc Monot; Chiara Tani; Patrizia Spigaglia; Fabrizio Barbanti; Nathalie Norais; Bruno Dupuy; Emilio Bouza; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

10.  Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country.

Authors:  A Lo Vecchio; L Lancella; C Tagliabue; C De Giacomo; S Garazzino; M Mainetti; L Cursi; E Borali; M V De Vita; E Boccuzzi; L Castellazzi; S Esposito; A Guarino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.